0000907654false00009076542024-02-022024-02-02

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 02, 2024

 

 

ARCA biopharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-22873

36-3855489

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

10170 Church Ranch Way

Suite 100

 

Westminster, Colorado

 

80021

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (720) 940-2200

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common

 

ABIO

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 2, 2024, Raymond L. Woosley, M.D., Ph.D. and Dan Mitchell each resigned from the board of directors (the “Board”) of ARCA biopharma, Inc., a Delaware corporation (“ARCA”), effective immediately. Upon the effectiveness of their resignations, Dr. Woosley and Mr. Mitchell each ceased to serve on any Board committees, including as Chairperson of the Nominating & Corporate Governance Committee and as member of the Compensation Committee, and as member of the Audit Committee and Nominating & Corporate Governance Committee, respectively. Each of Dr. Woosley’s and Mr. Mitchell’s resignation was not the result of any disagreement with ARCA on any matter relating to ARCA’s operations, policies or practices. In connection with Dr. Woosley’s and Mr. Mitchell’s resignations, the Board reduced the size of the Board from eight (8) to six (6) directors.

ARCA expresses its gratitude to Dr. Woosley and Mr. Mitchell for their years of invaluable and dedicated service.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

104

Cover Page Interactive Data File. The cover page XBRL tags are embedded within the inline XBRL document (contained in Exhibit 101).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ARCA biopharma, Inc.
(Registrant)

 

 

 

 

Date:

February 6, 2024

By:

/s/ C. Jeffrey Dekker

 

 

 

Name: C. Jeffrey Dekker
Title: Chief Financial Officer

 

v3.24.0.1
Document And Entity Information
Feb. 02, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 02, 2024
Entity Registrant Name ARCA biopharma, Inc.
Entity Central Index Key 0000907654
Entity Emerging Growth Company false
Entity File Number 000-22873
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 36-3855489
Entity Address, Address Line One 10170 Church Ranch Way
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Westminster
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80021
City Area Code (720)
Local Phone Number 940-2200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common
Trading Symbol ABIO
Security Exchange Name NASDAQ
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more ARCA Biopharma Charts.
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more ARCA Biopharma Charts.